In This Issue
In the Spotlight
Science in Society
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Zenocutuzumab, a HER2xHER3 bispecific antibody, reduces cell growth in NRG1-rearranged cancer cell lines and xenografts and induces durable clinical responses in patients with NRG1 fusion–positive tumors.
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
Pediatric, adolescent, and young adult patients underwent molecular profiling of their recurrent or refractory tumors as part of the MAPPYACTS trial, which identified actionable alterations and suggested a role for circulating tumor DNA for their identification within the blood.
Comprehensive genomic profiling of colorectal cancer shows that individuals of African ancestry have more frequent KRAS, APC, and PIK3CA somatic alterations compared with Europeans, while also demonstrating different trends in APC in young-onset disease.
Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma
Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer
Circulating tumor cells highly expressing Enpp1 contribute to local recurrence of breast cancer through immune modulation by increasing haptoglobin expression, which encourages infiltration of myeloid-derived suppressor cells and the formation of neutrophil extracellular traps.
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma
News in Brief
News in Depth